BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
September 11, 2017 at 01:46 AM EDT
* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA
